Capricor Therapeutics Faces Class Action Over Deramiocel Disclosures

The complaint filed against the San Diego-based company centers on the unauthorized modification of a statistical analysis plan. According to the court filing, Capricor altered its methodology for evaluating Deramiocel clinical data without securing necessary FDA approval. This omission allegedly rendered the company's subsequent Biologics License Application resubmission and related public disclosures materially misleading to shareholders.

DJS Law Group, led by attorney David J. Schwartz, is representing the class. Investors seeking to participate in the litigation or pursue lead plaintiff status are encouraged to contact the firm before the September 28 cutoff. While the firm emphasizes its background in high-stakes corporate governance and securities litigation, participation in this recovery effort does not strictly require an appointment as a lead plaintiff.